Technical Analysis for PRTC - PureTech Health plc

Grade Last Price % Change Price Change
D 20.83 2.36% 0.48
PRTC closed up 2.36 percent on Friday, November 1, 2024, on 18 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 50 DMA Bearish 2.36%
Bollinger Band Squeeze Range Contraction 2.36%
Narrow Range Bar Range Contraction 2.36%
Gapped Down Weakness 2.36%
50 DMA Support Bullish -0.05%
MACD Bullish Centerline Cross Bullish -0.05%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 19 hours ago
50 DMA Support about 19 hours ago
50 DMA Resistance about 19 hours ago
Gapped Up (Full) about 20 hours ago
Rose Above Previous Day's High about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

PureTech Health plc Description

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Immunology Health Sciences Medication Monoclonal Antibody Alzheimer's Disease Gastrointestinal Parkinson's Disease Urology Schizophrenia Biomarkers Milk Dementia Dysfunction Central Nervous System Disorders Psychiatry Specialty Drugs Nervous System Disorders Neurology Chronic Disease Hematologic Malignancies Choline Hematopoietic Stem Cell Immune Mediated Diseases Exosome Psychosis Galectin Inflammatory Disorders Biomarker Technology Cognitive Dysfunction Lymphedema

Is PRTC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 34.0
52 Week Low 17.08
Average Volume 6,081
200-Day Moving Average 24.47
50-Day Moving Average 20.64
20-Day Moving Average 20.33
10-Day Moving Average 20.56
Average True Range 0.85
RSI (14) 53.49
ADX 24.28
+DI 38.73
-DI 18.78
Chandelier Exit (Long, 3 ATRs) 19.14
Chandelier Exit (Short, 3 ATRs) 21.66
Upper Bollinger Bands 21.12
Lower Bollinger Band 19.53
Percent B (%b) 0.82
BandWidth 7.84
MACD Line 0.05
MACD Signal Line -0.04
MACD Histogram 0.0829
Fundamentals Value
Market Cap 562.31 Million
Num Shares 27 Million
EPS -1.70
Price-to-Earnings (P/E) Ratio -12.25
Price-to-Sales 55.13
Price-to-Book 1.25
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.60
Resistance 3 (R3) 21.55 21.25 21.47
Resistance 2 (R2) 21.25 21.06 21.27 21.42
Resistance 1 (R1) 21.04 20.93 20.89 21.09 21.38
Pivot Point 20.74 20.74 20.67 20.76 20.74
Support 1 (S1) 20.53 20.55 20.38 20.58 20.28
Support 2 (S2) 20.23 20.42 20.25 20.24
Support 3 (S3) 20.02 20.23 20.19
Support 4 (S4) 20.07